Search
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalThe drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.
Fendiline
go.drugbank.com/drugs/DB08980ApprovedWithdrawnIt has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.
Dopamine
go.drugbank.com/drugs/DB00988ApprovedInvestigationalOne of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regu...
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnBoth the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.
Oxytocin
go.drugbank.com/drugs/DB00107ApprovedInvestigationalVet approved[A229008,A228593] In the mid-1950s, synthetic oxytocin was successfully synthesized by a biochemist named Vincent du Vigneaud; he was later recognized with a Nobel prize for his work. … [A229113] Although most commonly linked to labor and delivery, oxytocin actually has broad peripheral and central effects.
Taurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigationalIt was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial
Elosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalIt was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process.